Camargo
NOVEMBER 11, 2020
In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks. Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, the U.S.
XTalks
AUGUST 17, 2020
To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 24, 2023
Every major pharma company is now involved in CGT development which has resulted in the approval of 28 therapies by the FDA thereby making CGT no longer a niche category of therapies. What are the general differences in the supply chain of CGT vs. traditional clinical trials? Differences in CGT vs traditional trials supply chain.
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
242 
Let's personalize your content